Mentari Therapeutics, Inc.
corporate_fare Company Profile
Mentari Therapeutics, Inc. (NASDAQ:MTRI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for MTRI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for MTRI spans 8-K.
Recent high-impact activity:
- Mentari Replaces Both Legacy Auditors with Deloitte Days After Merger Close
- Mentari Posts First Post-Merger Financials: $63.0M Nine-Month Loss, $45.8M Cash, $490M Raised
Financial Snapshot
Short Interest & Short Volume
On November 19, 2026, 35.2% of MTRI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.